Prostate cancer

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Science, Research, Oncology, Esophagus, Sensitivity, Prostate cancer, Survival rate, Patient, Lung, Exact sciences, Breast, Death, MD, Abstract, AACR, Cancer, Pancreas, Stomach, Liver, Ovary, Medical imaging

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

Key Points: 
  • Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.
  • These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening.
  • ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population.
  • Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.

Early is Good Announces Collaboration with Mayo Clinic to Develop a Comprehensive Liquid Biopsy Test for Men with Advanced Prostate Cancer

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Medical Devices, Health, Consumer, Men, Biotechnology, EIG, Prostate cancer, Disease, Education, Patient, Mayo Clinic, Research, Death, Cancer, Liquid biopsy, Integration platform, Pharmaceutical industry

Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.

Key Points: 
  • Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.
  • This collaboration to develop a comprehensive multi-omic test aims to significantly improve patient outcomes for men with advanced prostate cancer," says Thakshila Liyanage, Ph.D., Founder & CEO of Early is Good.
  • This novel liquid biopsy test seeks to enable comprehensive care plans for men with mCRPC.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

Genomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testing

Retrieved on: 
Tuesday, April 9, 2024
Health, MassMutual, Cardiovascular disease, Face, Prostate cancer, Learning, Disease, Partnership, Atrial fibrillation, Diabetes, Genetics, Risk, Patient, Ageing, DNA, Breast, Insurance, Risk assessment, Privacy, Nursing

OXFORD, England and SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives. The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases. The expansion follows a successful research collaboration in which more than 70% of policyowners who elected to use the risk assessment service reported intent to take preventative actions based on their risk scores, including plans to see their doctor or seek further screening.

Key Points: 
  • The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases.
  • Genomics' at-home test studies millions of small variations in DNA, generating polygenic risk scores, that can inform the likelihood of certain conditions.
  • During the initial Genomics and MassMutual research collaboration, 1 in 5 policyowners learned that they are at a higher risk for preventable diseases.
  • MassMutual only receives high-level, anonymized data from Genomics that allows the company to better understand aggregate policyowners' health and behaviors and interest in these types of offerings.

Hoag Announces $25 Million Gift to Boldly Hoag Campaign

Retrieved on: 
Monday, April 8, 2024
Health, Pacific Life, Prostate cancer, Bed, Environment, Patient, Cancer, Benjamin, Operating, Wood, Architecture, Heart, Hoag (health network), Hospital

IRVINE, Calif., April 8, 2024 /PRNewswire/ -- Scheduled to open in 2026, Hoag's reimagined Sun Family Campus in Irvine will be built around the Du Family Hospital Pavilion in honor of a generous $25 million gift from longtime philanthropists Ben and Carmela Du.

Key Points: 
  • Their first major gift to Hoag in 2015 established the Benjamin & Carmela Du Endowed Chair in Urologic Oncology, which continues to support breakthroughs in prostate cancer treatment at Hoag.
  • Ben and Carmela are also members of Hoag Innovators, a group of community leaders dedicated to catalyzing innovation at Hoag through the power of collective giving.
  • The Du family joins Diana and David Sun, the Pacific Life Foundation, and other visionary donors in Hoag's philanthropic community fueling a greater, more empowered health care future for all through the Hoag Hospital Foundation's ambitious $300 million Boldly Hoag campaign.
  • With more than $180 million raised toward the project, the Boldly Hoag campaign is about more than new buildings; it's about redefining what comes next for Hoag patients, staff, the community, and health care more broadly.

SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177

Retrieved on: 
Monday, April 8, 2024
Drug Master File, SHINE, Shine Technologies, Pupa, Patient, Ytterbium, Cancer, Prostate cancer, Cassiopeia, DMF, Food, Pharmaceutical industry

JANESVILLE, Wis., April 8, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, becomes North America's largest producer of non-carrier added lutetium-177 (n.c.a.

Key Points: 
  • JANESVILLE, Wis., April 8, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, becomes North America's largest producer of non-carrier added lutetium-177 (n.c.a.
  • Lu-177) chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File (DMF) to the U.S. Food and Drug Administration.
  • The DMF submission provides confidential, detailed information about SHINE's facilities, procedures, and articles utilized in drug manufacturing, processing, and storage.
  • By producing Lu-177 in North America, SHINE reduces transit times companies currently experience and diminishes the possibility of Lu-177's decay.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
Wednesday, March 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Retrieved on: 
Friday, March 15, 2024
Prostate cancer, SAN, Doctor of Philosophy, Therapy, Pharmaceutical industry

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.

Key Points: 
  • SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.
  • Oncternal’s President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research Biotech Analyst, Hartaj Singh and a prostate cancer Key Opinion Leader on Tuesday, March 19th, 2024 at 11:00 AM ET.
  • Dr. Breitmeyer will discuss the development of Oncternal’s novel dual-acting androgen receptor inhibitor, ONCT-534, the ongoing Phase 1/2 clinical trial ONCT-534-101, and the potential positioning of ONCT-534 within the treatment paradigm of advanced prostate cancer.
  • A replay of the event will be available online at investor.oncternal.com and it will be archived there for at least 30 days.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
Rat, Finance, Patient, Roche, Food and Drug Administration, Therapy, GLP, Rheumatology, Inflammasome, Research, Triple-negative breast cancer, CDK2, Public expenditure, Investigational New Drug, Cancer, VAV1, MGD, Prostate cancer, NSCLC, PD, Neoplasm, Inflammation, Senior, Dermatology, AACR, MYC, Poster, FDA, SCLC, DSM-IV codes, Administration, Growth, Fast Track, NLRP3, Toxicology, Research and development, Pharmaceutical industry

“We made excellent pipeline and corporate progress during 2023 and early 2024, highlighted by the encouraging initial clinical results reported from our MRT-2359 Phase 1/2 study in October.

Key Points: 
  • “We made excellent pipeline and corporate progress during 2023 and early 2024, highlighted by the encouraging initial clinical results reported from our MRT-2359 Phase 1/2 study in October.
  • Edmund has more than 25 years of experience as a finance professional and has been with Monte Rosa since March of 2021.
  • Monte Rosa expects to subsequently initiate proof-of-concept studies in autoimmune diseases spanning gastroenterology, dermatology, rheumatology, and neurology indications.
  • The increase of $54 million was primarily related to the proceeds from the Roche collaboration and registered direct offering in Q4 2023.